An elevated platelet count is a common finding in both hospitalized and ambulatory patients. Thrombosis and bleeding complications are more frequently observed in patients with clonal thrombocytosis than secondary thrombocytosis. The aim of this study was to investigate the behaviors of plasminogen activator inhibitor type 1 (PAI-1), the inhibitor of fibrinolysis; and thromboxane A2 and 6-keto-PGF1 α, the products of endoperoxides, in 16 patients affected with clonal thrombocytemia as compared with 16 patients with reactive thrombocytosis and 15 normal controls. In the clonal thrombocytemia group, plasma levels of PAI-1 antigen and activity were significantly higher than both reactive thrombocytosis and control group. Plasma levels of 6-keto-PGF1α were significantly higher in the clonal thrombocytemia group than the other two groups and also higher in the reactive thrombocytosis group than the control group, which was also significant. This study confirms that arachidonate metabolism is frequently deranged in patients with thrombocytosis and hypofibrinolysis due to increased PAI-1 plasma levels as shown in the clonal thrombocytosis group. This may explain the thrombotic tendency in myeloproliferative disorders.
Fenaux P, Simoni M, Caulier MT, et al.Clinical course of essential thrombocytemia in 147 cases. Cancer1990;66:549.
4.
Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the interaction between human plasminogen activator. Biochem1990;265:109.
5.
Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor and its function in fibrinolysis: an update. Fibrinolysis1995;9:263.
6.
Alessi MC, Chomiki N, Berthier R, et al.Detection of plasminogen activator inhibitor-1 mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost1994;72:931.
7.
Kokle BA, Schick PK, He X, et al.Plasminogen activator inhibitor 1 mRNA is expressed in platelets and megacaryocytes and the megakayoblastic cell line CHRF-288. Arterioscler Thromb1993;13:669.
8.
Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor in human blood. Thromb Haemost1986;55:325.
9.
Booth NA, Simpson AJ, Croll A, et al.Plasminogen activator inhibitor in plasma and platelets. Br J Haematol1988;70:327.
10.
Hadjez JM, Combe S, Horellou MH, et al.Heterogenous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis. Fibrinolysis1994;8:543.
11.
Patrassi GM, Sartori MT, Saggiorato G, et al.Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis1992;6:99.
12.
Patrassi GM, Sartori MT, Viero ML, et al.The fibrinolytic potential in patients with Cushing’s disease: A clue to their hypercoagulable state. Blood Coag Fibrinol1992;3:789.
13.
Patrassi GM, Sartori MT, Rigotti P, et al.Reduced fibrinolytic potential one year after kidney transplantation. Transplantation1995;59:1416.
14.
Russell NH, Salmon J, Keenan JP, Bellingham AJ. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res1981;22:389.
15.
Jubelirer SJ, Russell F, Vaillancourt R, Deykin D. Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood1980;56:728.
16.
Keenan JP, Wharton J, Shepherd AJN, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: A possible defect of prostaglandin synthesis. Br J Haematol1977;35:275.
17.
Okuma M, Ukino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood1979;54:1258.
18.
Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res1982;26:389.
19.
Patrono C, Ciabattoni G, Pinca E, et al.Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res1980;17:317.
20.
Langley R. Practical Statistics. New York, Dover, 1971.
21.
Mehta J, Metha P, Lawson DL, et al.Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: Evidence for synthesis of prostacyclin by leukocaytes from platelet derived endoperoxides. J Lab Clin Med1985;106:246.
22.
Declerck PJ, Alessi MC, Verstreken M, et al.Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood1988;71:220.
23.
Erikson E, Ranby M, Gyrender E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res1988;50:91.
24.
Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocytemia. A retrospective study of 103 patients. Cancer1991;67:2926.
25.
Pearson TC, Wethereley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet1978:1219.
26.
Randi ML, Fabris F, Tison T, et al.Prevalance of specific thrombotic accidents in patients with thrombocytosis. Haematologica1993;25:149.
27.
Fabris F, Randi ML, Sbrojavacca R, et al.The possible value of platelet aggregation studied in patients with increased platelet number. Blut1981;43:279.
28.
Pareti FJ, Gugliotta L, Mannucci L, et al.Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost1982;47:84.
29.
Wehmeier A, Scharp RE, Flicke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: Relation of platelet disorders to clinical aspects of the disease. Haemostasis1989;19:251.
30.
Luzzatto G, Fabris F, Mazzuccato M, Girolami A. PF4 versus βTG as evidence for platelet activation in myeloproliferative disorders. Scand J Haematol1985;35:299.
31.
Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocytemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, Protein S, PAI-1, t-PA and vWF. Thromb Haemost1993;70:736.
32.
Preston FE, Martin JF, Stewart RW, Davies-Jones GAB. Thrombocytosis, circulating platelet aggregates and neurological dysfunction. Br Med J1979;2:1561.
33.
Patrassi GM, Sartori MT, Rigotti P, et al.Coagulation and fibrinolysis during the first year of immunosuppressive treatment in renal transplantation: Correspondence between hypercoagulable state and steroid therapy. Clin Appl Thromb/Haemost1995;1:277.
34.
Patrassi GM, Sartori MT, Ruffatti A, et al.Fibrinolytic pattern in recurrent spontaneous abortions: No relationship between hypofibrinolysis and anti-phospholipid antibodies. Am J Hematol1994;47:266.
35.
Bazzan M, Tamponi G, Gallo E, et al.Fibrinolytic imbalance in essential thrombocytemia: Role of platelets. Haemostasis1993;23:38.
36.
Pannocchia A, Garis G, Giorgianni A, et al.Molecular characteristics of human plasma, platelet and vascular cell PAI-1. Comparison between normal and thrombocytemic subjects. Fibrinolysis1994;8:28.
37.
Canceras JA, Garcia-Avello A, Garcia-Frade LJ. Elevated plasma levels of plasminogen activator inhibitor in essential thrombocythemia and polycthemia vera. Haemostasis1994;24:311.
38.
Harlan JM, Harker LA. Hemostasis thromboembolic disorders. The role of arachidonic acid metabolites in platelet-vessel wall interactions. Med Clin North Am1981;65:855.
39.
Zahavi C, Zahavi M, Firsteter E, et al.An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol1991;47:326.
40.
Zahavi J, Zahavi M, Firsteter B, et al.An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol1991;47:326.
41.
Landolfi R, Ciabattoni P, Patrignani P, et al.Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood1992;80:1965.
42.
Rocca B, Ciabattoni G, Tartaglione R, et al.Increased thromboxane biosynthesis in essential thrombocytemia. Thromb Haemostas1995;74:1225.
43.
Schafer IA. Deficiency of platelet lipooxygenase activity in myeloproliferative disorders. N Engl J Med1982;306:381.
44.
Cortelazzo S, Viero P, Morelli C, et al.Normal vascular prostacyclin generation in patients with chronic myeloproliferative disorders. Thromb Res1985;39:139.
